Randomised placebo-controlled trial shows CBD may enhance functional connectivity in autistic children, indicating potential therapies.
Autistic children often show altered brain network connectivity, including circuitry implicated in social cognition. Cannabidiol (CBD) has emerged as a potential therapy for autism, but its neural mechanisms remain under-researched. Here, we report an analysis of resting-state electroencephalography (EEG) data collected as part of a double-blind, placebo-controlled crossover trial, to explore whether 12 weeks of oral CBD oil treatment could modulate functional connectivity in autistic children. Twenty-nine autistic children (5-12 years) completed two 12-week intervention periods (CBD and placebo, randomised) separated by an 8-week washout. Before and after each intervention period, five minutes of eyes-open resting-state EEG data were obtained from a subset of 19 participants (8 female). Functional connectivity was calculated across 16 electrode-pairs in the alpha, beta, theta, and gamma bands. Paired t-tests comparing post- versus pre-intervention connectivity values were Benjamini-Hochberg false discovery rate (FDR)-corrected within each band (pFDR < .05). Beta-band connectivity between the right frontal and right inferior-parietal electrodes increased following CBD (p < .001, pFDR = .016) and alpha connectivity showed an increase that did not remain following FDR correction (p = .036, pFDR = .071). No significant connectivity differences were observed following placebo for any frequency band (pFDR > .60). These findings provide preliminary evidence that CBD might enhance connectivity within social cognitive brain networks in autism but will require replication in larger samples.
No takes yet. Share an insight, caveat, or question.
Parrella et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: